The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
May precipitate during extended storage. Sonicate to solubilize the precipitates.
The AGE modified BSA was produced by reacting BSA with glycolaldehyde under sterile conditions followed by extensive dialysis and purification steps. Fluorescence of AGEs was confirmed by fluorescence spectrophotometry with Ex./Em. = 370/440 nm. Glycated BSA shows a 7000% increase in fluorescence in compared to control BSA.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Advanced glycation end products
The non enzymatic reaction of reducing carbohydrates with lysine side chains and N terminal amino groups of macromolecules (amino acids, proteins, phospholipids and nucleic acids) is called the Maillard reaction or glycation. The latter products of this process, termed advanced glycation end products (AGEs), adversely affect the functional properties of proteins, lipids and DNA.
In long lived tissue proteins, these chemical modifications accumulate with age and may contribute to the pathophysiology of ageing and long term complications of diabetes, atherosclerosis and renal failure.
Cell Membrane and Secreted
SDS-PAGE - AGE-BSA (ab51995)
4-20% SDS-PAGE of AGE-BSA: 10, 15 and 20 ug of AGE-BSA loaded in each lane under reducing conditions and stained with Coomassie Blue. AGE-BSA has a predicted MW of ~ 66.5 kDa
This product has been referenced in:
Wang M et al. TRB3 mediates advanced glycation end product-induced apoptosis of pancreatic ß-cells through the protein kinase C ß pathway. Int J Mol Med40:130-136 (2017).
Read more (PubMed: 28534945) »
Chen YS et al. Advanced glycation end products decrease collagen I levels in fibroblasts from the vaginal wall of patients with POP via the RAGE, MAPK and NF-?B pathways. Int J Mol Med40:987-998 (2017).
Read more (PubMed: 28849117) »